Similar Articles
Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
Canan Duman İlki, Tuncay Gündüz, Murat Kürtüncü, Zuhal Yapıcı, Serra Sencer, Mefküre Eraksoy
DOI: 10.4274/tnd.2019.77010
Issue: 2020, Volume 26 - Issue 1
0
1193
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir
DOI: 10.4274/tnd.62144
Issue: 2017, Volume 23 - Issue 4
0
1058
Weight Loss and Fingolimod
Nefati Kıylıoğlu
DOI: 10.4274/tnd.87528
Issue: 2017, Volume 23 - Issue 4
0
781
The effect of fingolimod on complete blood count, lipid panel, and relationship with clinicoradiologic features in patients with multiple sclerosis
Furkan Sarıdaş, Sarah Hamide Lazrak, Emine Rabia Koç, Güven Özkaya, Ömer Faruk Turan
DOI: 10.55697/tnd.2025.213
Issue: 2025, Volume 31 - Issue 4
115
137